[go: up one dir, main page]

SV2006002165A - Regimenes y kits de progestina ciclica ref. am101677 - Google Patents

Regimenes y kits de progestina ciclica ref. am101677

Info

Publication number
SV2006002165A
SV2006002165A SV2005002165A SV2005002165A SV2006002165A SV 2006002165 A SV2006002165 A SV 2006002165A SV 2005002165 A SV2005002165 A SV 2005002165A SV 2005002165 A SV2005002165 A SV 2005002165A SV 2006002165 A SV2006002165 A SV 2006002165A
Authority
SV
El Salvador
Prior art keywords
progestine
regimes
cyclical
ref
kits
Prior art date
Application number
SV2005002165A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002165A publication Critical patent/SV2006002165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN METODO DE ANTICONCEPCION QUE INCLUYE LA ADMINISTRACION DE 21 A 27 DIAS CONSECUTIVOS, DE UNA PROGESTINA EN AUSENCIA DE UN ESTROGENO U OTRO COMPUESTO ESTEROIDE, SEGUIDO DE 1 A 7 DIAS SIN UNA CANTIDAD EFECTIVA DE UN AGENTE ACTIVO. SE DESCRIBE, ADEMAS, UN KIT UTIL DESDE EL PUNTO DE VISTA FARMACUETICO PARA FACILITAR LA ADMINISTRACION DE ESTE REGIMEN
SV2005002165A 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica ref. am101677 SV2006002165A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07

Publications (1)

Publication Number Publication Date
SV2006002165A true SV2006002165A (es) 2006-05-09

Family

ID=35064935

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002165A SV2006002165A (es) 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica ref. am101677

Country Status (14)

Country Link
US (3) US20060009428A1 (es)
EP (1) EP1773344A1 (es)
JP (2) JP5288796B2 (es)
CN (2) CN1980676A (es)
AR (1) AR049707A1 (es)
AU (1) AU2005269938A1 (es)
BR (1) BRPI0512991A (es)
CA (1) CA2571377C (es)
MX (1) MXPA06014579A (es)
PA (1) PA8638601A1 (es)
PE (1) PE20060378A1 (es)
SV (1) SV2006002165A (es)
TW (1) TW200603813A (es)
WO (1) WO2006014476A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2005269938A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
DE602006013114D1 (de) * 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
BRPI0611250A2 (pt) 2005-06-09 2011-02-15 Wyeth Corp composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
BR112012019725A2 (pt) * 2010-02-08 2020-11-10 Tao Tom Du usos de uma composição farmacêutica e uso de pelo menos um progestogênio
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MY187233A (en) * 2015-06-23 2021-09-13 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception
WO2024218800A1 (en) * 2023-04-21 2024-10-24 Akums Drugs And Pharmaceuticals Limited Vaginal drug delivery system of dydrogesterone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
ATE209919T1 (de) * 1987-09-24 2001-12-15 Jencap Res Ltd Oestrogen und progestin enthaltende verhütungspackungen
BR9710566A (pt) 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
AU4134599A (en) * 1998-04-07 1999-10-25 Akzo Nobel N.V. Progestogen-only contraceptive kit
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
EP1175411B1 (en) * 1999-05-04 2008-02-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
SI20853A (sl) * 1999-08-31 2002-10-31 Jenapharm Gmbh & Co. Kg Mezoprogestini (modulatorji receptorja progesterona) kot sestavina ženskih kontraceptivov
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1665510A (zh) * 2002-06-25 2005-09-07 惠氏公司 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
AU2005269938A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
US8604027B2 (en) 2013-12-10
CA2571377A1 (en) 2006-02-09
US20140094458A1 (en) 2014-04-03
TW200603813A (en) 2006-02-01
US20060009428A1 (en) 2006-01-12
JP2013040181A (ja) 2013-02-28
BRPI0512991A (pt) 2008-04-22
AR049707A1 (es) 2006-08-30
US20100292198A1 (en) 2010-11-18
AU2005269938A1 (en) 2006-02-09
MXPA06014579A (es) 2007-03-01
PA8638601A1 (es) 2006-07-03
CN104208067A (zh) 2014-12-17
JP2008505909A (ja) 2008-02-28
JP5288796B2 (ja) 2013-09-11
PE20060378A1 (es) 2006-06-02
CN1980676A (zh) 2007-06-13
WO2006014476A1 (en) 2006-02-09
CA2571377C (en) 2014-03-25
EP1773344A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
SV2006002165A (es) Regimenes y kits de progestina ciclica ref. am101677
GT200500186A (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
AR044964A1 (es) Formulaciones para microproyecciones recubiertas que contienen contra-iones no volatiles
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
NO20054681L (no) Farmasoytiske produkter
ECSP088422A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
AR046824A1 (es) Composicion y aparato para la administracion transdermica.
NO20054682L (no) Sikker transdermal doseringsform
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
ES2137372T3 (es) Solucion antifungica para las uñas.
ECSP056159A (es) Composición de fármaco conjugado
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
CL2009000541A1 (es) Uso de una enzima degradadora de matriz activable (amde) para la formulacion de un medicamento de administracion sub-epidermica; composicion farmacologica y su uso; combinacion que comprende a amde, un activador y un agente; recipiente para amde y para el activador; kit que comprende dicho recipiente
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
AR109263A2 (es) Composición que comprende moxidectina
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
BRPI0417585A (pt) composição pregabalina
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
GT200600126A (es) Oblea que contiene hormonas estoides
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
AR042111A1 (es) Semillas recubiertas y metodo para recubrir semillas
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
DK1250125T3 (da) Farmaceutiske præparater, som indeholder terbinafin

Legal Events

Date Code Title Description
FD Lapse